Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Chem Biol. 2011 Dec 23;18(12):1602-10. doi: 10.1016/j.chembiol.2011.09.016.

    Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors.

    Source

    Department of Immunology and Infectious Disease, Harvard School of Public Health, Boston, MA 02115, USA.

    Abstract

    Here we report the discovery of tetracyclic benzothiazepines (BTZs) as highly potent and selective antimalarials along with the identification of the Plasmodium falciparum cytochrome bc(1) complex as the primary functional target of this novel compound class. Investigation of the structure activity relationship within this previously unexplored chemical scaffold has yielded inhibitors with low nanomolar activity. A combined approach employing genetically modified parasites, biochemical profiling, and resistance selection validated inhibition of cytochrome bc(1) activity, an essential component of the parasite respiratory chain and target of the widely used antimalarial drug atovaquone, as the mode of action of this novel compound class. Resistance to atovaquone is eroding the efficacy of this widely used antimalarial drug. Intriguingly, BTZ-based inhibitors retain activity against atovaquone resistant parasites, suggesting this chemical class may provide an alternative to atovaquone in combination therapy.

    Copyright © 2011 Elsevier Ltd. All rights reserved.

    PMID:
    22195562
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3474356
    Free PMC Article

    Images from this publication.See all images (4)Free text

    Figure 1
    Figure 2
    Figure 3
    Figure 4

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk